All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 4th European CAR T-Cell Meeting, the ALL Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv, IL. We asked, how do CAR T-cell recipients respond to COVID-19 vaccination?
How do CAR T-cell recipients respond to COVID-19 vaccination?
In this video, Nagler discusses chimeric antigen receptor (CAR) T-cell therapy (CAR-T). He also highlights the challenges that COVID-19 has caused to CAR-T and the implications for patients with; Non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?
During the 4th European CAR T-Cell Meeting, the ALL Hub was pleased to speak with Daniel Chen, University College Hospitals, London, UK. We asked,...
How should we treat a patient who has a molecular relapse after transplant?
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Lori Muffly, Stanford University, Stanford, US. We asked, How should we...
Subscribe to get the best content related to ALL delivered to your inbox